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Purpose: To quantitatively compare the dosimetric and biologic differences in treatment plans 
from flattened and flattening-filter-free (FFF) beam for three anatomic cancer sites.  
Methods and Materials: Treatment plans with static intensity-modulated radiotherapy beams 
and volumetric modulated arc therapy beams were generated for 13 patients for both the 
flattened beam and the FFF beam of the TrueBeam system. Beam energies of 6 MV and 10 MV 
were chosen for planning. A total of 104 treatment plans were generated in 13 patients. In order 
to analyze the biological effectiveness of treatment plans, dose volume histograms (DVH) were 
utilized.  Flattened and FFF beam plans are quantitatively compared. 
Results: In head and neck cases, for VMAT plans, dose reduction in the FFF beam plans 
compared to the flattened beam in left cochlea, right submandibular gland and right parotid gland 
reached up to 2.36 Gy, 1.21 Gy and 1.45 Gy, respectively. Similarly, for static IMRT plans, the 
dose reduction of the FFF beam plans compared to the flattened beam plans for the same organs 
reached up to 0.34 Gy, 1.36 Gy and 1.46 Gy, respectively. Overall, for head and neck, the FFF 
beam plans achieved mean dose reduction of up to 5%, 7% and 9%, respectively for above 
organs at risk. For lung and prostate cases, the FFF beams provided lower or comparable NTCP 
values to organ-at-risk (OAR) compared to the flattened beam for all plans. 
Conclusions: In general, we observed treatment plans utilizing FFF beams can improve dose 
sparing to OARs without compromising the target coverage. Significant dose sparing effect is 
obtained for head and neck cancer cases, especially for the cases with relatively large field sizes 
(≈ 16 × 20 𝑐𝑚2). For lung and prostate cases, compared to the flattened beam, the FFF beam 
based treatment plans provide lower or comparable dose to most OARs.  
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Introduction 
 
Intensity-modulated radiation therapy (IMRT) techniques have led to improved conformal dose 
delivery methods. Modern IMRT techniques include static step-and-shoot IMRT, rotational 
IMRT (e.g. volumetric modulated arc therapy (VMAT)(1) and helical Tomotherapy (2). In 
contrast to the 3D-conformal radiotherapy (3D-CRT), IMRT provides improved dose conformity 
to the target as well as steeper dose gradients to surrounding tissues, which may lead to better 
local tumor control (3). However, probability of increased dose to surrounding tissues is 
comparatively higher in IMRT than 3D-CRT. The typical ratio of monitor units (MU) between 
the IMRT plan and the 3D-CRT plan is in the range of 3 to 5. This contributes to higher leakage 
from the gantry head and consequently increased dose to normal tissues and whole body in 
general (4, 5). This undesirable dose is likely to result in higher normal tissue complication 
probability (NTCP) (6). Furthermore, IMRT tends to have a prolonged treatment time to deliver 
dose compared to 3D-CRT. Several studies have highlighted that these limitations of IMRT may 
lead to increased probability of radiation induced secondary cancer (4). It is therefore desirable 
to reduce the unnecessary scatter from the gantry head and shorten the treatment time for IMRT 
delivery. The removal of the flattening filter has been a logical choice to reduce the scatter.  
The flattening filter was first introduced to provide flat dose profiles at a certain depth. The 
development of IMRT eliminates the need for a flattening filter in modern linear accelerator 
(linac) systems. In recent years, the application of the flattening-filter-free (FFF) photon beam 
has been studied extensively (5, 7-16). Forward peaked dose profile is the major characteristic of 
the FFF beam (17-22). Compared with the flattened beam, the FFF beam also has increased dose 
rate (8-12), reduced dose to OAR (12), reduced neutron contamination for high energy beams 
(>15 MV) (23) and reduced uncertainty in dose calculation (8). Thus, clinical application of the 
FFF beam would lead to reduced treatment time (11) and secondary cancer risk induced by 
radiation (11, 13). 
 
Several clinical comparative studies have investigated the differences between the flattened 
beam and the FFF beam (23-29). Most of these clinical comparison studies focused on the time 
efficiency obtained from the high dose rate of the FFF beam compared with the flattened beam. 
The dosimetric and biological differences between the flattened beam and the FFF beam for 
static IMRT and VMAT plans with typical (≈ 10 × 10 𝑐𝑚2) and large field sizes (≈ 16 ×
20 𝑐𝑚2) are not well understood. In the presented study, 6 MV and 10 MV beams were selected 
to design the treatment plans. Three clinical sites were used to investigate the dosimetric and 
biologic differences treatment plans using the flattened beam and the FFF beam. Static IMRT 
and VMAT techniques were utilized in this study.  
 
 
Materials and Methods 
 
Patient selection 
 
Thirteen anonymized patients with three anatomical cancer sites: head and neck, lung and 
prostate were studied. A case number was assigned to refer to each anonymized patient. Standard 
clinical constrains were provided by the physician for planning target volume (PTV) and OARs. 
These were applied to generate the treatment plans. The dose prescriptions were selected from 
the typical dose range prescribed by the physicians. For head and neck cases, the dose 
prescription ranged from 60 Gy to 70 Gy at 2 - 2.5 Gy/fraction. For lung cases, the dose 
prescription ranged from 45 Gy to 60 Gy at 1.5 - 2 Gy/fraction. For prostate cases, dose 
prescriptions ranged from 70 Gy to 78 Gy at 2 - 2.5 Gy/fraction.  
 
 
RT planning techniques 
 
A Varian TrueBeam (Varian Medical Systems, Palo Alto, CA) linac was commissioned on the 
Eclipse
TM
 treatment planning system (TPS) (version 10.0). An Anisotropic-Analytical-Algorithm 
(AAA) was used to calculate the dose for both static IMRT and VMAT plans. The dose grid in 
the calculation was 2.5 mm for all plans. Photon beam energies of 6 MV and 10 MV were 
selected for this study. Beam modalities included flattened and FFF beams. All treatment 
parameters such as iso-center position, beam angle, arc number and field size were set to be 
identical for the flattened and the FFF beam plans. High definition 120 leaf MLC (2.5 mm width 
in the center and 5 mm width in the peripheral) was used to generate all treatment plans.  
 
For each patient, 8 treatment plans were generated, including 6 MV (10 MV) flattened static 
IMRT plan, 6 MV (10 MV) FFF static IMRT plan, 6 MV (10 MV) flattened VMAT plan and 6 
MV (10 MV) FFF VMAT plan. In the FFF beam mode, the maximum dose rate increases from 
600 MU/min to 1400 MU/min for the 6 MV and to 2400 MU/min for the 10 MV photon beam. 
For the VMAT plans with FFF beams, the TPS automatically selects the optimal dose rate during 
the optimization process. In our study, the optimal dose rates of the VMAT plans are lower than 
the maximum dose rates of the FFF beam for both the energies. For treatment plans with large 
field sizes (e.g. ≈ 16 × 20 𝑐𝑚2  in case 2), the optimal dose rates of the VMAT plans were 
largely reduced (e.g. about 350 MU/min in case 2 for 6 MV beam) from the maximum dose 
rates of the FFF beam. For static IMRT plans, a constant dose rate of 600 MU/min was applied 
to design the treatment plans. This eliminated the influence of the speed limit of the multi-leaf 
collimator (MLC). For all treatment plans, the normal tissue fall-off function was set to be same 
for all plans. The optimization processes were repeated five times for all static IMRT and VMAT 
plans in order to get an optimal dose distribution. 
 
DICOM files were exported from the Eclipse workstation for all cases. CERR (the 
Computational Environment for Radiotherapy Research(30)) was used to calculate dose-volume-
histogram (DVH) from the DICOM file. In-house developed Matlab codes (Math Works, Natick, 
MA) were used to calculate the dosimetric and biological doses and to perform statistical 
analysis. The dosimetric results were benchmarked with the Eclipse software system for each 
case and acceptable agreement was observed. 
 
Treatment plan evaluation  
 
Target coverage and dose to OARs were analyzed to evaluate the treatment plans for all cases. 
For all treatment plans, 95% of the target volume was normalized to 95% of the dose 
prescription for evaluation and optimization. The criteria used to evaluate the target coverage 
included conformity index (CI), target coverage (TC), conformity number (CN) and gradient 
index (GI). These are defined as (31):
 
 𝐶𝐼 = 𝑇𝑉95 𝑃𝑇𝑉95⁄ (1) 
𝑇𝐶 = 𝑃𝑇𝑉95 𝑃𝑇𝑉⁄   (2) 
𝐶𝑁 = 𝐶𝐼 𝑇𝐶⁄      (3) 
𝐺𝐼 = 𝑇𝑉50 𝑇𝑉95⁄     (4) 
 
In Eq. 1-Eq. 4, 𝑇𝑉95 and 𝑃𝑇𝑉95  refer to the treated volume and the planning target volume 
(PTV) covered by the 95% dose line. A value closer to one indicates better target coverage for 
all indices. A paired sample t-test (32) was applied to analyze the statistical differences of target 
coverage among patients (statistical significance, 𝑝 ≤ 0.05).  
 
Besides the physical dose, biological doses including biological effective dose (BED) (33) and 
equivalent uniform dose (EUD) (34-36)) were also calculated. Using Gay and Niemierko's model 
(36), tumor control probability (TCP) and normal tissue complication probability (NTCP) were 
calculated for targets and OARs respectively by using the calculated EUD. Biological parameters 
(𝛼 𝛽⁄ , 𝑇𝐷50, 𝑇𝐶𝐷50, 𝑎 and 𝛾50) were selected from the published references (36-41). 
 
 
 
 
 
 
 Results 
 
The dose distribution of one selected patient from each studied site is shown in Fig.1. The DVHs 
of one patient are selected from each treatment site and are shown in Fig 2 and Fig 3. Target 
coverage for the FFF beam is comparable to the flattened beam for both static IMRT and VMAT 
plans (𝑝 > 0.05). Significant differences between the flattened beam and the FFF beam were 
observed for the VMAT plans in lung cancer cases. For VMAT plans, the FFF beam provides a 
higher relative mean dose (𝐷𝑚𝑒𝑎𝑛 𝐷𝑥⁄ ) to the target compared with the flattened beam for both 6 
MV and 10 MV beams. For the static IMRT plans, the difference between the flattened beam and 
the FFF beam is not significant. The target coverage analysis for head and neck and lung cases is 
shown in Table e1 and Table e2. For other treatment sites, the differences between the flattened 
beam and the FFF beam are not significant (𝑝 ≤ 0.05).  
 
Comparisons of dose to OARs between the flattened beam and the FFF beam are shown in Table 
1- Table 3. Among the three cancer sites, the dose sparing effect of the FFF beam is significant 
in head and neck cases. For certain OARs such as left cochlea, larynx and right submandibular 
gland, noticeable dose sparing effect is obtained by the FFF beam compared to the flattened 
beam. In Table 1, for static IMRT plans, the FFF beam has the most significant dose sparing 
effect compared to the flattened beam on larynx and right submandibular gland. Compared to the 
flattened beam, the FFF beam reduces mean dose up to 2.05 Gy and 1.36 Gy for larynx and right 
submandibular, respectively, for 10 MV beam. For VMAT plans, left cochlea and larynx show 
the best dose sparing effect from the FFF beam compared to the flattened beam. The mean dose 
reductions come up to 2.36 and 2.82 Gy, respectively. Compared with the static IMRT plans, the 
VMAT plans show considerable differences between the flattened beam and the FFF beam. 
Relative dose ratio between the flattened beam and the FFF beam for five head and neck cases 
are shown in Table 3e. For left cochlea, larynx and right submandibular gland, the mean dose 
reduction of the FFF beam compared to the flattened beam reaches up to 5%, 3% and 5%, 
respectively. 
 
For the lung cancer case, as shown in Fig 2- Fig 3, larynx has the most significant dose sparing 
effect from the FFF beam compared to the flattened beam, both for 10 MV static IMRT and 
VMAT plans. In Table 2, the reduction in the mean dose for the FFF beam compared to the 
flattened beam is 1.6 Gy for larynx. For other organs, comparable doses are obtained by the FFF 
beam and flattened beam for static IMRT and VMAT plans in both beam energies. Relative dose 
ratio between the flattened beam and the FFF beam for four lung cases is shown in Table 4e. For 
organs such as heart and lungs, the FFF beam compared to the flattened beam, tends to provide 
higher maximum dose of 2% and 3%, respectively. , This effect is more significant in the 10 MV 
VMAT lung plans compared with the three other plans. 
 
For the prostate cancer, for both VMAT and static IMRT plans, the FFF beam provides a 
comparable or improved dose sparing effect to OARs. The dosimetric and biological dose and 
NTCP values of a selected prostate case are shown in Table 3. The maximum reduction in the 
mean dose is obtained for the right hip (1.03 Gy) in the 10 MV VMAT plan compared to the 
flattened beam. The relative dose ratio between the flattened beam and the FFF beam for 4 
patients is shown in Table 5e. For rectum, in VMAT plans, the FFF beam provided slightly 
higher (1%) maximum dose compared to the flattened beam.. For all OAR, the FFF beam 
provided improved dose sparing effect and NTCP values compared to the flattened beam.  
 
Discussion 
 
Overall, in our clinical comparison of the head and neck cases the differences between the FFF 
beam and the flattened beam are significant for both 6 MV and 10 MV beams. For lung and 
prostate, results were comparable. Head and neck cases required relatively larger field size to 
cover the target. As shown in Fig 1, large field sizes (~16 × 20 𝑐𝑚2) were used to cover the 
target. For the VMAT plans, two arcs with different iso-centers were used to provide the 
required dose coverage for the PTVs. In other cancer sites, typical field sizes (≈ 10 × 10 𝑐𝑚2) 
were used to create the treatment plans. 
 
The noticeable dose sparing effect of the FFF beam compared with the flattened beam for large 
treatment field size is due to the forward peak beam profiles of the FFF beam. There is no 
observable difference between the beam profiles of flattened beam and FFF beam for small field 
size (e.g. 6 × 6 𝑐𝑚2). For relatively large field sizes (e.g. 16 × 20 𝑐𝑚2), the FFF beam provided 
lower dose to the out-of-field region compared with the flattened beam for both 6 MV and 10 
MV beams. This is of clinical significance for cases receiving a high radiation dose (~ 70 Gy) 
and having a diversity of sensitive normal tissue structures as found in the head and neck region. 
When we increased the beam energy from 6 MV to 10 MV, the dose reduction effect in the out-
of-field region was significant for the FFF beam compared to the flattened beam. This fact also 
explains the improved dose sparing effect of the FFF beam in head and neck cases in both 10 
MV static IMRT and VMAT plans compared to the 6 MV plans.  
 
 
However, due to the non-uniform beam profile of the FFF beam, compared to the flattened beam, 
the FFF beam tends to use more MUs to deliver the uniform dose to target. In our clinical 
investigation, the ratio of MUs between the FFF beam plans and the flattened beam plans was 
typically around 1.3 for the static IMRT and VMAT plans. The higher MUs of the FFF beam 
may lead to increased dose leakage from the MLC and escalated dose to OARs. Based on our 
investigation, even with the increased leakage dose from MLC, the FFF beam can still provide 
comparable dose sparing effect to OARs in most cases. 
 
Randomized studies have documented dosimetric improvement to OARs using IMRT has 
dramatically improved overall toxicity outcomes and quality of life for patients (42-44). Despite 
these improvements, both acute and late toxicity represent on going challenges to successful 
head and neck cancer treatments. In the cases we examined, the lower dose to submandibular 
glands and parotid glands could all contribute to lower xerostomia rates as the mean dose to each 
of these OARs has been directly associated with xerostomia (45).  In the dose range where 
xerostomia (45) is likely, a linear correlation with the mean dose is apparent suggesting even 
modest dose improvement may have a clinical impact. Other toxicities that may be affected 
include voice quality, swallowing function, breathing function and cataract development.  In 
head and neck, for both static IMRT and VMAT plans, the flattened beam and the FFF beam 
provided improved dose sparing to right parotid gland and right submandibular gland. Clearly, 
the FFF beam provided a significant dose sparing effect to the right submandibular gland 
compared to the flattened beam and should lead to a lower probability of xerostomia. The higher 
larynx dose associated with a flattened beam may contribute to poor voice quality, as the larynx 
mean dose has been correlated with laryngeal edema (47). The late toxicity of radiation treatment 
is directly related to both the overall dose and the dose per fraction. The lower mean and 
maximal doses achieved to OAR reduces both the total delivered dose to several critical organs, 
as well as the daily fraction size. Thus, FFF treatment for the examined head and neck cases may 
allow for the same TCP coverage with a decreased risk of late side effects of treatment.  
 
Conclusion 
 
In this manuscript, 13 clinical cancer cases for three anatomical sites were investigated to 
analyze the dosimetric and biologic differences between the flattened and the FFF beam plans in 
terms of target coverage and dose to OARs. It was observed that the FFF beam provides 
comparable target coverage to the flattened beam in all 3 sites of cancer. The FFF beam for head 
and neck cancer obtained observable dose sparing. For other two sites, the FFF beam provided 
improved dose sparing effect to most of the OARs. For certain OARs such as the heart in the 
VMAT plan for lung cancer, the FFF beam delivered higher maximum dose. Due to the speed 
limit of the MLC, the maximum dose rate of the FFF beam may be considerably lower than the 
theoretical maximum dose rate value, especially for large field sizes. 
 
 
 
 
 
  
Fig. 1. Dose distribution for 6 MV head and neck (left column), lung (middle column) and 
prostate (right column) patients for one plan per case. From top to bottom, it shows the static 
IMRT flattened plans, static IMRT FFF plans, VMAT flattened plans and VMAT FFF plans. 
  
Fig 2.    Normalized treatment plans comparison between the flattened and the FFF beams for the static 
IMRT and the VMAT plans for beam energy 6 MV. Selected cases include head and neck case,  lung case 
and prostate case. The solid lines are the flattened beam plans and the dashed lines are the FFF beam 
plans. 
 
 
 
Fig. 3.    Normalized treatment plans comparison between the flattened and the FFF beams for the static 
IMRT and the VMAT plans for beam energy 10 MV. Selected cases include head and neck case and lung 
case and prostate case. The solid lines are the flattened beam plans and the dashed lines are the FFF beam 
plans. 
 
 
 
 
 
 
 
 
Table 1 Physical dose, biological dose and NTCP values for OARs in the head and neck case #2. 
Dose Prescription/Fraction Number: 60 Gy/30 fx 
  Flattened Beam FFF Beam 
OAR 
Max  
Dose 
(Gy) 
Mean  
Dose 
(Gy) 
Mean  
BED 
(Gy) 
NTCP 
 
Max  
Dose 
(Gy) 
Mean  
Dose 
(Gy) 
Mean  
BED 
(Gy) 
NTCP 
 
6 MV IMRT 
Left Cochlea 42.88 24.28 31.85 1.02E-04 42.92 23.32 30.52 9.42E-05 
Larynx 59.18 38.72 54.02 2.53E-04 59.38 37.49 51.91 2.03E-04 
Right Parotid 27.81 18.80 22.98 2.94E-09 27.99 18.21 22.18 1.56E-09 
Right  
Submandibular 29.95 23.92 30.33 1.77E-07 28.71 23.41 29.55 1.19E-07 
Brainstem 35.94 6.92 8.12 8.45E-08 35.94 6.18 7.30 9.11E-08 
Cord 42.50 23.84 32.35 1.96E-06 42.10 22.90 30.84 1.12E-06 
10 MV IMRT 
Left Cochlea 39.45 23.37 30.22 2.33E-05 40.67 23.03 29.90 4.00E-05 
Larynx 59.21 39.84 55.95 3.03E-04 58.75 37.78 52.37 1.65E-04 
Right Parotid 25.38 17.39 20.93 7.11E-10 24.18 15.94 18.94 1.35E-10 
Right  
Submandibular 
28.68 23.36 29.47 1.16E-07 26.97 22.01 27.43 3.60E-08 
Brainstem 35.15 6.12 7.20 6.14E-08 35.35 5.44 6.48 7.95E-08 
Cord 42.79 24.09 32.82 2.61E-06 42.02 23.00 31.05 1.19E-06 
6 MV VMAT 
Left Cochlea 28.85 24.48 31.17 2.72E-07 27.49 23.28 29.35 1.09E-07 
Larynx 59.80 37.65 51.97 1.27E-04 59.41 36.04 49.25 9.64E-05 
Right Parotid 22.37 16.23 19.22 2.18E-10 21.96 15.64 18.42 1.11E-10 
Right  
Submandibular 
26.75 22.83 28.68 7.42E-08 26.29 22.40 28.03 5.06E-08 
Brainstem 37.47 10.88 12.71 1.29E-07 38.38 10.23 11.93 1.43E-07 
Cord 42.57 21.59 28.82 8.00E-07 42.03 20.46 26.99 4.40E-07 
10 MV VMAT 
Left Cochlea 29.74 25.62 32.95 5.60E-07 27.21 23.26 29.30 9.40E-08 
Larynx 59.16 38.57 53.63 1.56E-04 58.91 35.76 48.81 1.01E-04 
Right Parotid 21.56 15.08 17.66 5.56E-11 19.68 13.63 15.74 8.82E-12 
Right  
Submandibular 
26.77 22.33 27.93 4.91E-08 26.46 21.12 26.13 1.82E-08 
Brainstem 39.07 11.44 13.50 2.96E-07 39.11 10.01 11.71 1.90E-07 
Cord 42.80 21.99 29.59 1.27E-06 41.56 20.58 27.27 5.25E-07 
 
 
 
 
 
 
Table 2 Physical dose, biological dose and NTCP values for OARs in the lung case #7. 
Dose Prescription/Fraction Number: 66 Gy/33 fx 
  Flattened Beam FFF Beam 
OAR 
Max  
Dose 
(Gy) 
Mean  
Dose 
(Gy) 
Mean  
BED 
(Gy) 
NTCP 
 
Max  
Dose 
(Gy) 
Mean  
Dose 
(Gy) 
Mean  
BED 
(Gy) 
NTCP 
 
6 MV IMRT 
Cord 39.69 19.99 25.48 1.27E-07 39.60 19.69 25.10 1.16E-07 
Esophagus 69.57 30.37 45.20 5.77E-02 70.73 30.11 44.89 8.36E-02 
Heart 48.18 2.76 2.99 6.74E-12 47.81 2.37 2.55 3.79E-12 
Larynx 56.84 32.83 43.61 1.38E-05 56.91 32.09 42.59 1.61E-05 
Lungs 69.30 18.26 24.97 6.51E-05 70.15 17.91 24.52 5.62E-05 
10 MV IMRT 
Cord 39.79 19.86 25.34 1.38E-07 38.70 19.30 24.54 8.90E-08 
Esophagus 68.57 30.48 45.49 4.65E-02 69.21 30.14 45.00 5.64E-02 
Heart 47.69 2.36 2.58 9.26E-12 47.84 1.97 2.15 5.43E-12 
Larynx 56.57 33.50 44.64 1.67E-05 56.44 31.90 42.22 1.12E-05 
Lungs 68.80 18.37 25.22 7.04E-05 69.35 17.93 24.61 5.78E-05 
6 MV VMAT 
Cord 43.33 21.93 28.67 9.19E-07 43.83 21.66 28.38 1.11E-06 
Esophagus 70.93 31.49 47.29 4.76E-02 71.89 31.38 47.23 5.31E-02 
Heart 49.66 2.82 3.04 3.29E-12 50.69 2.44 2.64 4.34E-12 
Larynx 63.50 28.08 36.60 5.38E-06 64.35 28.01 36.64 7.01E-06 
Lungs 71.97 18.97 26.12 9.32E-05 74.08 18.62 25.69 8.15E-05 
10 MV VMAT 
Cord 43.20 21.88 28.71 1.08E-06 42.23 21.35 27.91 8.92E-07 
Esophagus 71.43 31.89 48.27 5.66E-02 70.64 32.06 48.71 4.79E-02 
Heart 49.38 2.34 2.54 3.95E-12 48.88 2.03 2.22 5.46E-12 
Larynx 62.93 29.30 38.41 7.67E-06 62.83 27.70 36.01 4.69E-06 
Lungs 74.65 19.01 26.33 9.94E-05 77.76 19.05 26.52 1.05E-04 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Physical dose, biological dose and NTCP values for OARs in the prostate case #11. 
Dose Prescription/Fraction Number: 78 Gy/39 fx 
  Flattened Beam FFF Beam 
OAR 
Max  
Dose 
(Gy) 
Mean  
Dose 
(Gy) 
Mean  
BED 
(Gy) 
NTCP 
Max  
Dose 
(Gy) 
Mean  
Dose 
(Gy) 
Mean  
BED 
(Gy) 
NTCP 
6 MV IMRT 
Rectum 77.68 27.46 37.94 1.82E-03 77.71 27.14 37.46 1.70E-03 
Bladder 79.39 20.41 29.24 1.89E-04 79.39 20.79 29.98 2.79E-04 
Right Hip 38.93 22.75 27.78 4.66E-07 38.89 22.40 27.31 4.02E-07 
Left Hip 35.64 24.25 29.79 8.31E-07 36.26 23.88 29.30 7.84E-07 
Penile  
Bulb 
6.06 3.92 4.06 3.13E-21 5.58 3.64 3.76 8.68E-22 
10 MV IMRT 
Rectum 77.43 27.46 38.04 1.86E-03 77.40 27.18 37.62 1.85E-03 
Bladder 79.14 19.17 27.26 8.51E-05 79.52 19.39 27.73 1.13E-04 
Right Hip 38.09 22.97 28.02 4.16E-07 36.79 22.83 27.84 3.93E-07 
Left Hip 34.76 24.49 30.04 6.81E-07 35.01 24.28 29.80 7.27E-07 
Penile  
Bulb 
6.27 3.36 3.46 8.53E-22 5.56 2.97 3.06 1.14E-22 
6 MV VMAT 
Rectum 77.23 29.86 42.17 2.82E-03 78.22 29.00 40.87 2.73E-03 
Bladder 79.19 21.04 29.31 8.11E-05 80.80 20.69 28.84 7.25E-05 
Right Hip 28.26 16.41 18.85 3.40E-10 27.05 15.53 17.73 1.43E-10 
Left Hip 29.86 15.69 17.93 2.60E-10 29.53 14.82 16.84 1.32E-10 
Penile  
Bulb 
7.25 4.68 4.87 5.85E-20 6.53 4.15 4.31 8.55E-21 
10 MV VMAT 
Rectum 77.76 29.15 41.12 2.51E-03 78.14 28.31 39.88 2.88E-03 
Bladder 78.80 20.23 28.15 5.60E-05 79.79 19.68 27.37 4.38E-05 
Right Hip 27.14 15.61 17.82 1.48E-10 25.28 14.58 16.51 3.81E-11 
Left Hip 29.34 14.72 16.71 9.85E-11 29.27 14.46 16.39 8.74E-11 
Penile  
Bulb 
7.14 3.94 4.08 9.35E-21 6.06 3.30 3.40 5.34E-22 
 
 
 
 
 
 
 
 
 
Table e1. Target coverage analysis for head and neck cases (n=5). 
Head and Neck 
VMAT 
  6 MV 10 MV 
Parameter Flattened FFF p Flattened FFF p 
𝐷𝑚𝑒𝑎𝑛 𝐷𝑥⁄  0.99±0.03 0.99±0.02 0.9 1.00±0.02 1.00±0.02 0.65 
CI 1.20±0.15 1.28±0.29 0.31 1.42±0.36 1.46±0.45 0.62 
CN 1.26±0.16 1.34±0.30 0.31 1.50±0.38 1.54±0.47 0.62 
GI 10.79±10.60 8.83±7.08 0.29 8.40±7.20 7.44±5.47 0.29 
TCP 0.84±0.14 0.84±0.14 0.75 0.85±0.14 0.85±0.14 0.35 
IMRT 
Parameter Flattened FFF p Flattened FFF p 
𝐷𝑚𝑒𝑎𝑛 𝐷𝑥⁄  0.99±0.01 0.99±0.02 0.08 0.99±0.01 0.99±0.01 0.32 
CI 1.26±0.14 1.27±0.15 0.21 1.22±0.11 1.22±0.11 0.82 
CN 1.32±0.15 1.34±0.16 0.21 1.29±0.12 1.29±0.12 0.82 
GI 10.80±10.98 10.42±10.53 0.13 11.03±11.67 10.43±10.60 0.28 
TCP 0.84±0.14 0.84±0.14 0.13 0.84±0.15 0.84±0.15 0.44 
 
 
Table e2. Target coverage analysis for lung cases (n=4).  
Lung 
VMAT 
  6 MV 10 MV 
Parameter Flattened FFF p Flattened FFF p 
𝐷𝑚𝑒𝑎𝑛 𝐷𝑥⁄  1.01±0.02 1.02±0.02 0.01 1.03±0.02 1.04±0.01 0.04 
CI 1.11±0.11 1.12±0.11 0.06 1.12±0.12 1.13±0.10 0.91 
CN 1.17±0.12 1.18±0.12 0.06 1.18±0.12 1.19±0.10 0.92 
GI 3.30±0.18 3.27±0.16 0.1 3.14±0.19 3.12±0.19 0.29 
TCP 0.71±0.06 0.72±0.06 0.34 0.72±0.06 0.72±0.06 0.03 
IMRT 
Parameter Flattened FFF p Flattened FFF p 
𝐷𝑚𝑒𝑎𝑛 𝐷𝑥⁄  1.01±0.01 1.01±0.01 0.86 1.01±0.02 1.01±0.02 0.77 
CI 1.15±0.03 1.16±0.03 0.12 1.14±0.03 1.14±0.02 0.89 
CN 1.21±0.03 1.22±0.03 0.12 1.20±0.03 1.20±0.03 0.89 
GI 3.38±0.40 3.37±0.41 0.46 3.25±0.42 3.19±0.40 0.07 
TCP 0.71±0.06 0.71±0.06 0.59 0.71±0.06 0.71±0.06 0.89 
 
Table e3. Relative dose and NTCP ratio (FFF/flattened) to OARs for head and neck cases (n=5). 
VMAT 
  6 MV 10 MV 
OAR 
Mean 
Dose 
Ratio 
Max 
Dose 
Ratio 
NTCP 
Ratio 
Mean 
Dose 
Ratio 
Max 
Dose 
Ratio 
NTCP 
Ratio 
Left Cochlea 0.97±0.02 0.96±0.02 0.56±0.22 0.95±0.06 0.94±0.04 0.53±0.51 
Larynx 0.98±0.02 1.00±0.01 0.87±0.23 0.97±0.04 1.00±0.02 0.89±0.25 
Cord 0.96±0.01 1.00±0.02 0.73±0.25 0.98±0.03 1.00±0.03 0.97±0.60 
Brainstem 0.87±0.11 0.90±0.13 0.50±0.47 0.86±0.09 0.91±0.11 0.45±0.37 
Right parotid 0.91±0.06 0.95±0.04 0.25±0.22 0.92±0.03 0.95±0.03 0.21±0.14 
Right 
submandibular  
0.94±0.04 0.98±0.01 0.53±0.13 0.93±0.02 0.98±0.04 0.48±0.34 
IMRT 
  6 MV 10 MV 
OARs 
Mean 
Dose 
Ratio 
Max 
Dose 
Ratio 
NTCP 
Ratio 
Mean 
dose 
Ratio 
Max dose 
Ratio 
NTCP 
Ratio 
Left cochlea 0.97±0.01 0.98±0.02 0.74±0.25 0.96±0.04 0.99±0.06 0.98±1.04 
Larynx 0.98±0.01 1.00±0.00 0.98±0.12 0.98±0.02 1.01±0.02 0.94±0.29 
Cord 0.97±0.01 0.98±0.01 0.70±0.16 0.97±0.02 0.99±0.01 0.71±0.19 
Brainstem 0.91±0.02 0.96±0.06 0.73±0.40 0.88±0.05 0.92±0.09 0.56±0.48 
Right parotid 0.97±0.02 1.01±0.01 0.53±0.29 0.95±0.04 0.98±0.02 0.45±0.46 
Right 
submandibular  
 
0.97±0.02 
 
0.98±0.02 
 
0.74±0.17 
 
0.97±0.03 
 
0.98±0.03 
 
0.72±0.37  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table e4. Relative dose and NTCP ratio (FFF/flattened) to OARs for lung cases (n=4). 
VMAT 
  6 MV 10 MV 
OARs 
Mean dose 
ratio 
Max dose 
ratio 
NTCP ratio 
Mean dose 
ratio 
Max dose 
ratio 
NTCP ratio 
Cord 0.99±0.01 1.01±0.01 1.20±0.18 0.98±0.01 1.00±0.02 0.92±0.2 
Esophagus 0.99±0.01 1.01±0.00 1.10±0.05 1.00±0.01 1.01±0.02 1.18±0.31 
Heart 0.94±0.06 1.01±0.02 1.08±0.25 0.95±0.06 1.02±0.02 1.25±0.16 
Larynx 0.95±0.06 1.00±0.02 0.84±0.65 0.94±0.00 1.01±0.02 0.76±0.21 
Lungs 0.99±0.01 1.01±0.02 0.94±0.06 1.00±0.01 1.03±0.02 1.00±0.17 
IMRT 
  6 MV 10 MV 
OARs 
Mean dose 
ratio 
Max dose 
ratio 
NTCP ratio 
Mean dose 
ratio 
Max dose 
ratio 
NTCP ratio 
Cord 0.98±0.02 1.00±0.01 0.85±0.21 0.97±0.01 0.98±0.01 0.65±0.17 
Esophagus 0.99±0.01 1.01±0.01 1.14±0.21 0.98±0.00 1.01±0.00 1.06±0.12 
Heart 0.94±0.06 1.00±0.01 0.84±0.19 0.92±0.06 1.01±0.00 0.76±0.16 
Larynx 0.94±0.05 0.99±0.02 0.79±0.53 0.92±0.04 0.98±0.02 0.48±0.26 
Lungs 0.98±0.01 1.01±0.01 0.88±0.06 0.98±0.00 1.01±0.00 0.83±0.02 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table e5. Relative dose and NTCP ratio (FFF/flattened) to OARs for prostate cases (n=4). 
VMAT 
  6 MV 10 MV 
OARs 
Mean dose 
ratio 
Max dose 
ratio 
NTCP ratio 
Mean dose 
ratio 
Max dose 
ratio 
NTCP ratio 
Rectum 0.99±0.01 1.01±0.01 1.10±0.11 0.99±0.02 1.00±0.00 1.07±0.06 
Bladder 0.96±0.04 1.02±0.01 0.71±0.34 0.98±0.02 1.01±0.00 0.91±0.23 
Right 
Hip 0.97±0.02 0.97±0.02 0.57±0.23 0.96±0.04 0.96±0.04 0.52±0.42 
Left Hip 0.97±0.02 0.99±0.01 0.64±0.24 0.97±0.04 0.99±0.03 0.79±0.48 
Penile 
 Bulb 
0.86±0.07 0.87±0.08 0.12±0.08 0.87±0.02 0.89±0.03 0.10±0.03 
IMRT 
  6 MV 10 MV 
OARs 
Mean dose 
ratio 
Max dose 
ratio 
NTCP ratio 
Mean dose 
ratio 
Max dose 
ratio 
NTCP ratio 
Rectum 0.98±0.01 1.00±0.00 0.95±0.02 0.99±0.00 1.00±0.00 0.98±0.03 
Bladder 0.99±0.02 1.00±0.00 0.98±0.38 0.99±0.02 1.00±0.00 0.94±0.29 
Right 
Hip 0.98±0.02 1.00±0.01 0.84±0.29 0.98±0.01 0.98±0.02 0.84±0.22 
Left Hip 0.98±0.02 1.00±0.02 0.86±0.24 0.99±0.01 1.00±0.02 0.87±0.21 
Penile 
 Bulb 
0.92±0.02 0.92±0.03 0.25±0.07 0.89±0.02 0.9±0.04 0.19±0.15 
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